Siegall C B, Liggitt D, Chace D, Mixan B, Sugai J, Davidson T, Steinitz M
Molecular Immunology Department, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA.
Clin Cancer Res. 1997 Mar;3(3):339-45.
Clinical trials of immunotoxins in cancer patients have been limited in many cases by vascular leak syndrome (VLS). Recently, rats were identified as a model for VLS induced by BR96 sFv-PE40, a carcinoma-reactive single-chain immunotoxin. In this study, the toxin component of this immunotoxin, PE40, was found to be responsible for inducing hydrothorax in rats, thereby demonstrating that direct binding to the BR96 antigen was not essential to the onset of VLS. Mutational analysis of PE40 determined that both ADP ribosylation and proteolytic processing functions innate to Pseudomonas exotoxin A (PE) were necessary for PE40 to induce hydrothorax in rats; however, neither function by itself was sufficient for VLS induction. Additionally, nonsteroidal anti-inflammatory agents were found to block VLS in rats receiving BR96 sFv-PE40. These results demonstrate that the toxin component of PE-based immunotoxins induce VLS and suggest agents for clinical management of the toxicity.
在许多情况下,免疫毒素在癌症患者中的临床试验受到血管渗漏综合征(VLS)的限制。最近,大鼠被确定为一种由BR96 sFv-PE40(一种癌反应性单链免疫毒素)诱导的VLS模型。在本研究中,发现这种免疫毒素的毒素成分PE40是导致大鼠胸腔积液的原因,从而表明直接结合BR96抗原对于VLS的发生并非必不可少。对PE40的突变分析确定,铜绿假单胞菌外毒素A(PE)固有的ADP核糖基化和蛋白水解加工功能对于PE40诱导大鼠胸腔积液都是必需的;然而,单独任何一种功能都不足以诱导VLS。此外,发现非甾体抗炎药可阻断接受BR96 sFv-PE40的大鼠的VLS。这些结果表明基于PE的免疫毒素的毒素成分可诱导VLS,并提示了用于该毒性临床管理的药物。